These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 16937451

  • 1. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, Xu JM.
    World J Gastroenterol; 2006 Aug 07; 12(29):4750-3. PubMed ID: 16937451
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
    Hu YM, Xu JM, Mei Q, Xu XH, Xu SY.
    Acta Pharmacol Sin; 2005 Mar 07; 26(3):384-8. PubMed ID: 15715938
    [Abstract] [Full Text] [Related]

  • 3. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP, Xu JM, Hu YM, Mei Q, Xu XH.
    J Clin Pharm Ther; 2007 Oct 07; 32(5):517-24. PubMed ID: 17875119
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Jun 07; 15(6):793-803. PubMed ID: 11380317
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T.
    Eur J Clin Pharmacol; 2001 Sep 07; 57(6-7):485-92. PubMed ID: 11699613
    [Abstract] [Full Text] [Related]

  • 6. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U.
    Int J Clin Pharmacol Ther; 2006 Jul 07; 44(7):297-302. PubMed ID: 16961157
    [Abstract] [Full Text] [Related]

  • 7. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct 07; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 8. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2004 Oct 07; 76(4):290-301. PubMed ID: 15470328
    [Abstract] [Full Text] [Related]

  • 9. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
    Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishizaki T.
    Pharmacogenetics; 2001 Jun 07; 11(4):341-8. PubMed ID: 11434512
    [Abstract] [Full Text] [Related]

  • 10. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
    Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Dec 07; 15(12):1929-37. PubMed ID: 11736724
    [Abstract] [Full Text] [Related]

  • 11. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
    Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T.
    Clin Pharmacol Ther; 1999 May 07; 65(5):552-61. PubMed ID: 10340921
    [Abstract] [Full Text] [Related]

  • 12. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
    Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH.
    Pharmacotherapy; 2003 Jun 07; 23(6):711-9. PubMed ID: 12820812
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ.
    Eur J Clin Pharmacol; 2006 Feb 07; 62(2):107-12. PubMed ID: 16402242
    [Abstract] [Full Text] [Related]

  • 14. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct 07; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method.
    Chen ZY, Xie HT, Zheng QS, Sun RY, Hu G.
    Eur J Drug Metab Pharmacokinet; 2006 Oct 07; 31(1):27-33. PubMed ID: 16715780
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H.
    J Gastroenterol Hepatol; 2003 Sep 07; 18(9):1034-8. PubMed ID: 12911659
    [Abstract] [Full Text] [Related]

  • 18. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan 07; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 19. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.
    Helicobacter; 2008 Dec 07; 13(6):532-41. PubMed ID: 19166419
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.